BMJ:社区获得性肺炎(CAP)患者入院时血糖水平高,预示死亡风险增加

2012-06-17 刘伟杰 编译 中国医学论坛报

Fig 1Cumulative incidence of death (%) within 90 days in participants with community acquired pneumonia stratified by serum glucose levels on admission overall (n=6016) (top) and without diabetes (n=5

An external file that holds a picture, illustration, etc.
Object name is lepp001743.f1_default.jpg Object name is lepp001743.f1_default.jpg

Fig 1 Cumulative incidence of death (%) within 90 days in participants with community acquired pneumonia stratified by serum glucose levels on admission overall (n=6016) (top) and without diabetes (n=5141) (bottom). The 875 participants with missing data for serum glucose levels on admission were not included in these calculations for patients at risk

  一项多国联合研究显示,既往无糖尿病,但入院时有急性高血糖症的社区获得性肺炎(CAP)患者面临更高的死亡风险。论文5月29日在线发表于《英国医学杂志》(BMJ)。

  研究者共收集了2003年~2009年间来自德国、瑞士和奥地利的6891例CAP患者数据,在校正性别、年龄、当前吸烟状况、CAP严重程度及各种共病因素后,评估了入院时不同血糖水平与患者28、90和180天死亡率的相关性。

  结果为,既往无糖尿病但入院时血糖水平升高,是CAP患者28天和90天内死亡的预测因子。与入院时血糖水平正常者相比,存在轻度急性高血糖症者(血糖水平6~10.99 mmol/L)90天内死亡风险显著增加[危险比(HR)=1.56,P<0.001],当患者入院时血糖水平≥14 mmol/L时,90天内死亡风险也随之进一步升高(HR=2.37,P<0.001)。此外,与无糖尿病患者相比,既往患糖尿病者总体死亡率显著升高(HR=2.47,P<0.001)。这一结果不受入院时患者血糖水平的影响(P=0.18)。

原始文献:

Lepper PM, Ott S, Nüesch E, von Eynatten M, Schumann C, Pletz MW, Mealing NM, Welte T, Bauer TT, Suttorp N, Jüni P, Bals R, Rohde G; on behalf of the German Community Acquired Pneumonia Competence Network (CAPNETZ).Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ. 2012 May 28;344:e3397. doi: 10.1136/bmj.e3397.

免费全文下载PDF (558K)



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897927, encodeId=0f08189e927a2, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Mar 30 22:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042535, encodeId=6b6e2042535f0, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Jan 01 12:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847459, encodeId=587e184e45974, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Jan 22 04:03:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972013, encodeId=f2e619e20134c, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Jun 22 02:03:00 CST 2012, time=2012-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255406, encodeId=ac2b1255406f5, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395586, encodeId=cb19139558609, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2013-03-30 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897927, encodeId=0f08189e927a2, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Mar 30 22:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042535, encodeId=6b6e2042535f0, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Jan 01 12:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847459, encodeId=587e184e45974, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Jan 22 04:03:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972013, encodeId=f2e619e20134c, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Jun 22 02:03:00 CST 2012, time=2012-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255406, encodeId=ac2b1255406f5, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395586, encodeId=cb19139558609, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897927, encodeId=0f08189e927a2, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Mar 30 22:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042535, encodeId=6b6e2042535f0, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Jan 01 12:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847459, encodeId=587e184e45974, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Jan 22 04:03:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972013, encodeId=f2e619e20134c, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Jun 22 02:03:00 CST 2012, time=2012-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255406, encodeId=ac2b1255406f5, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395586, encodeId=cb19139558609, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2013-01-22 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897927, encodeId=0f08189e927a2, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Mar 30 22:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042535, encodeId=6b6e2042535f0, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Jan 01 12:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847459, encodeId=587e184e45974, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Jan 22 04:03:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972013, encodeId=f2e619e20134c, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Jun 22 02:03:00 CST 2012, time=2012-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255406, encodeId=ac2b1255406f5, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395586, encodeId=cb19139558609, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897927, encodeId=0f08189e927a2, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Mar 30 22:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042535, encodeId=6b6e2042535f0, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Jan 01 12:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847459, encodeId=587e184e45974, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Jan 22 04:03:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972013, encodeId=f2e619e20134c, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Jun 22 02:03:00 CST 2012, time=2012-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255406, encodeId=ac2b1255406f5, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395586, encodeId=cb19139558609, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1897927, encodeId=0f08189e927a2, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Mar 30 22:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042535, encodeId=6b6e2042535f0, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Tue Jan 01 12:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847459, encodeId=587e184e45974, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Jan 22 04:03:00 CST 2013, time=2013-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972013, encodeId=f2e619e20134c, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Jun 22 02:03:00 CST 2012, time=2012-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255406, encodeId=ac2b1255406f5, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395586, encodeId=cb19139558609, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]

相关资讯

美国婴幼儿及儿童社区获得性肺炎(CAP)指南公布

  为有效预防、诊治婴幼儿及儿童社区获得性肺炎(CAP),儿科感染性疾病学会(PIDS)和美国感染性疾病学会(IDSA)共同出台了其首个婴幼儿及儿童CAP诊治指南。整部指南共涉及诊断、治疗、预防等20个方面、92条推荐意见。该指南8月30日在线发布于《临床感染性疾病杂志》(Clin Infect Dis)。   现将其中有关何种患儿须住院治疗、门诊CAP可疑患儿应接受何种检查

病例讨论:循证诊治社区获得性肺炎患者一例

来源:中国医学论坛报  北京协和医院 吴东 黄晓明 王玉   CAP诊治要点   ● 由于病原学检查耗时长及阳性率低,对绝大多数社区获得性肺炎(CAP)患者须经验性治疗。   ● 对于重症CAP患者,即使抗生素选择无误,疗效显现仍需要2 ~ 4 天,医生应及时处理心衰和脓胸等并发症。   ● 合理应用无创通气可赢得CAP治疗时间,改善患者预后,但医生应严格筛选患者,密观病情变化,